TIS provides testing for patients to determine if they have HLA alleles defining genetic susceptibility with diseases or hypersensitivities to certain drugs. The presence or absence of the HLA allele can affect the clinical management of the patient. Confirmatory HLA typing is recommended for pharmacogenetic HLA associations due to the risk to the patient.
Well-documented HLA allele associations with these diseases and pharmacogenetic hypersensitivities can be invoiced through the Medicare schedule in some states (VIC, NSW). Testing for disease associations or drug hypersensitivities that are not eligible for Medicare invoicing is subject to written informed financial consent from the patient.
For patients that are part of a clinical trial, refer to the TIS External Clinical Trials and Research page for further information.
Refer to the tables below for well-documented HLA allele associations with diseases and drug sensitivities. For testing outside the below list, please contact the relevant laboratory.
- HLA allele associations with diseases and drug sensitivities
Pharmacogenetics HLA allele association Medicare rebate (Y/N) Abacavir hypersensitivity
(includes Abacavir-based drugs if trial participant is not indicated)B*57:01
(also see Flucloxacillin)Y Allopurinol hypersensitivity B*58:01 Y Augmentin hypersensitivity
(Amoxicillin-Clavulanatic acid)DRB1*15:01 and
DQB1*06:02Y Carbamazepine (Tegretol), oxcarbazepine, Lamotrigine, Phenytoin hypersensitivity or Steven-Johnson syndrome B*15:02, 15:08, 15:11, 15:21 or A*31:01 or A *24:02 Y Dapsone hypersensitivity B*13:01 Y Flucloxacillin drug-induced liver injury (DILI) B*57:01 Y Tebentefusp for Melanoma (Uveal/ocular) A*02:01 Y Vancomycin hypersensitivity A*32:01 Y Actinic prurigo DRB1*04:07 Y Ankylosing spondylitis B*27 Y Anti-IgLON5 Disease DRB1*10:01, DQB1*05:01 Y Arthritis B*27 Y Auto-immune hepatitis DRB1*03, DRB1*04 or DRB1*07 Y Behçet’s disease B*51 (B5) Y Birdshot retinopathy/choroidopathy/posterior uveitis A*29 Y Coeliac disease DQB1*02 and/or DQA1*05, DQB1*03:02 (DQ2/DQ8) Y Dermatitis herpetiformis DQB1*02 and/or DQA1*05, DQB1*03:02 (DQ2/DQ8) Y Goodpasture’s syndrome DRB1*15 Y Juvenile idiopathic arthritis B*27 Y Narcolepsy (with cataplexy) DQB1*06:02 Y Psoriasis vulgaris C*06 Y Psoriatic arthritis B*27 Y Polyarthritis B*27 Y Reiter’s disease or Reactive arthritis, Juvenile chronic arthritis B*27 Y Rheumatoid arthritis B*27, DRB1*04 Y Spondyloarthropathy B*27 Y Uveitis, acute anterior uveitis or iritis B*51 (B5), B*27 Y Vogt-Koyanagi-Harada Disease (VKH) DRB1*04 Y Addison’s Disease DRB1*03:01 and DQB1*02; or DRB1*04:04 and DQB1*03 N Alopecia areata DRB1*04 and DQB1*03; or DRB1*11 and DQB1*03 N Graves’ disease B*08, DRB1*03:01 N Hashimoto’s thyroiditis DRB1*03 N Myasthenia gravis DRB1*03:01, 07 N Recurrent Miscarriage N/A N Sjogren’s or Sicca Syndrome DRB1*03:01, DRB1*15 N Strontium ranelate HLA-A*33:03 or B*58:01 N Systemic lupus erythematosus (SLE) DRB1*03 N
- Testing
Tests performed including turnaround time NSW & VIC - HLA typing - low resolution (LabType)
SA - HLA Class I + II (A,B,C,DR,DQ, DP) Typing - high resolution
Request form NSW - FRM-01679 - Immunogenetics Service
Sample and labelling requirements FRM-02565 - Sample and volume requirements Storage and transport Storage and transport at room temperature.
Samples should be received by the laboratory within 24 hours of collection.
Ensure samples are packed in a secure container and the outside of the transport container is clearly labelled with the delivery address.
Invoicing Contact relevant laboratory Special instructions The following information is required for Medicare eligible tests:
Patient Medicare number and post code, requesting doctors name and provider number and the clinical reason for testing.